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ABSTRACT
Introduction: Every fifth ischemic stroke is caused by thromboembolism originating from an
atherosclerotic carotid artery plaque. While prevention is the most cost-effective stroke therapy,
antiplatelet and cholesterol-lowering drugs have a ceiling effect in their efficacy. Therefore, dis-
covery of novel pathophysiologic targets are needed to improve the primary and secondary pre-
vention of stroke. This article provides a detailed study design and protocol of HeCES2, an
observational prospective cohort study with the objective to investigate the pathophysiology of
carotid atherosclerosis.
Materials and Methods: Recruitment and carotid endarterectomies of the study patients with
carotid atherosclerosis were performed from October 2012 to September 2015. After brain and
carotid artery imaging, endarterectomised carotid plaques (CPs) and blood samples were
collected from 500 patients for detailed biochemical and molecular analyses.
Findings to date: We developed a morphological grading for macroscopic characteristics within
CPs. The dominant macroscopic CP characteristics were: smoothness 62%, ulceration 61%, intra-
plaque hemorrhage 60%, atheromatous gruel 59%, luminal coral-type calcification 34%, abundant
(44%) and moderate (39%) intramural calcification, and symptom-causing “hot spot” area 53%.
Future plans: By combining clinically oriented and basic biomedical research, this large-scale
study attempts to untangle the pathophysiological perplexities of human carotid atherosclerosis.
KEY MESSAGES
 This article is a rationale and design of the HeCES2 study that is an observational prospective
cohort study with the objective to investigate the pathophysiology of carotid atherosclerosis.
 The HeCES2 study strives to develop diagnostic algorithms including radiologic imaging to
identify carotid atherosclerosis patients who warrant surgical treatment.
 In addition, the study aims at finding out new tools for clinical risk stratification as well as
novel molecular targets for drug development.
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Atherosclerotic cardiovascular diseases (ASCVD) consti-
tute the largest cause of mortality in the graying
Western world and the incidence is surging also in
Eastern Europe, South America, Africa and Asia. [1].
Prevalent risk factors such as obesity, hypertension,
dyslipidemia, smoking, unhealthy dietary habits and
sedentary lifestyle aggravate the atherosclerotic
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vascular process and increase cardiovascular events.
The result has been a tremendous increase in the
overall disease burden at the population level [2].
Although the risk scores available today can identify
individuals at high risk, large proportions of such indi-
viduals remain unidentified. Moreover, prevention of
ASCVD by attacking the risk factors at an individual
level has proven difficult.
By investigating the plaque dissected on carotid
endarterectomy (CEA), investigators studying carotid
artery atherosclerosis can exploit direct access to the
cellular contents, which have or have not yet culmi-
nated in a clinically discernible symptom. They have
alluded to an outstanding opportunity to use the
carotid plaque material to establish a characteristic
gene expression pattern or even a “fingerprint” that
reflects either the stability or the progression of the
atherosclerotic process throughout the entire cardio-
vascular system in order to predict systemic vascular
outcomes [3]. Supporting evidence arises from post-
mortem observations in victims of myocardial infarc-
tion, revealing that, in addition to the culprit plaque,
also other coronary plaques demonstrate significantly
increased inflammation [4]. In addition, it has been
observed that when coronary disease presents with
unstable clinical symptoms, CP morphology is also
more unstable [5]. Finally, when atherosclerosis has
reached an advanced stage with clinical symptoms,
such as in the case of large-vessel peripheral arterial
disease of the lower limbs, or in the carotid arteries,
the patients have a high risk of acute myocardial
infarction, that is the development of a vulnerable cor-
onary plaque which will cause an acute, often fatal,
atherothrombotic event [6,7]. These findings support
the idea that instability of the vascular wall is a sys-
temic process and thus, a single atherosclerotic plaque
could provide information on the inflammatory status
of plaques elsewhere in the vascular system [3].
Recent observations of the predictive value of dis-
crete magnetic resonance imaging (MRI) characteristics
of a carotid plaque (CP) have reinstated the concept
of a vulnerable plaque in cerebrovascular disease and
stroke. In a recent meta-analysis of CP MRI and stroke
risk, the hazard ratios for intraplaque hemorrhage,
lipid-rich necrotic core, and thinning/rupture of the
fibrous cap as predictors of subsequent stroke/transi-
ent ischemic attack (TIA) were 4.59 (95% CI, 2.91–7.24),
3.00 (1.51–5.95), and 5.93 (2.65–13.20), respectively [8].
The virtue of therapeutic removal of plaques of this
nature to prevent strokes validates the vulnerable pla-
que paradigm inasmuch as it validates the CEA pro-
cedure itself. Still, imaging represents only one facet
of ongoing search for valuable local or circulating bio-
markers to improve stratification of stroke risk due to
carotid atherosclerosis.
We have 20 years of research experience on multi-
disciplinary and longitudinal research in many aspects
of carotid artery disease, based on previously explored
different aspects of symptom-causing carotid artery
disease in the Helsinki Carotid Endarterectomy Study
(HeCES) cohort (see below). Our previous research
identified a multitude of novel symptom-related
molecular, hemodynamic and cognitive observations
of a consecutive cohort of stenosing advanced carotid
atherosclerosis, and building on these findings, it is
the purpose of this report to outline in detail the
methods used in the collection of CP specimens from
500 carotid patients in Helsinki to establish an
extended biomarker database and enable more effi-
cient discovery of novel drug targets.
Past progress in Helsinki Carotid Endarterectomy
Study (HeCES)
The HeCES study started in 1997 in order to shed light
into the still elusive reasons why some plaques
advance even into complete occlusion without caus-
ing any clinical symptoms while others cause strokes.
The original study included 92 consecutive patients
with a high-grade carotid stenosis (>70%) who under-
went CEA in the Helsinki University Hospital dur-
ing 1997–2000.
Focusing on CP destabilization, our previous HeCES
study has revealed associations with CP morphology
and histology [9–11], gene expression of iron/haeme
metabolism (HO-1, CD163) [12] and proteins related to
intraplaque hemorrhage (PLIN2/adipophilin, CD163)
[13,14]. We performed a microarray study which pre-
sented a comprehensive transcriptional profiling of
stroke-associated CPs and demonstrated a significant
transcriptome “fingerprint” difference between stroke-
associated and silent CPs [15]. Some important genes
emerged from that study were, for example, FABP4
[15,16] and haptoglobin [17]. In addition to the bio-
chemical and morphological CP analyses, we have also
studied radiological brain findings and cognition
[18–21], as well as future risk to thromboembolic com-
plications in other vascular beds [7], in patients with
high-grade carotid stenosis.
Objectives
This observational study focuses on five objectives tar-
geting the most pressing problems in the prevention
of cardiovascular events in carotid artery disease.
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 To unravel the dominating pathomechanisms,
which govern the destabilization of an atheroscler-
otic plaque and may have evolved over decades.
 To develop a novel, clinically meaningful carotid
artery-specific plaque classification score by com-
bining data from detailed photographic and histo-
logic morphologic examination of the culprit lesion
with imaging findings and clinical data.
 To find new tools for clinical risk stratification, such
as circulating biochemical markers or genetic var-
iants, in order to identify individuals with especially
high or low risk of thromboembolism.
 Based on clinically characterized patient material,
to find novel molecular targets useful for drug
development and to find out whether some of
them are statin-sensitive.
 To clarify which biomedical factors or genotypes
represent long-term risk of restenosis, recurrent
stroke or premature cardiac death based on 10-
year follow-up.
Materials and methods
The HeCES 2 study is a cross-sectional and longitu-
dinal prospective consecutive cohort study that was
conducted at Helsinki University Hospital (HUH) in
Finland in collaboration with the departments of neur-
ology, vascular surgery and radiology. Recruitment of
patients started during October 2012 and was contin-
ued consecutively until September 2015 to include
altogether the predefined number of 500 symptomatic
and asymptomatic carotid atherosclerosis patients
scheduled for CEA. The CPs and blood samples were
collected for detailed analyses and patients were inter-
viewed and examined thoroughly. After this main
recruitment period, the collection of bilaterally oper-
ated plaques as well as the recruitment for the brain
and eye substudy (HECES-BEST, see Supplemental file
p. 12) is still ongoing. The study was approved by the
Ethics Committee of medicine of the Hospital District
of Helsinki and Uusimaa, and all study patients gave
written informed consent.
Patients
Patients were referred to CEA from the Hospital
District of Helsinki and Uusimaa, and the decisions to
perform CEA were based on the guidelines of
European Stroke Organization [22]. A computed tom-
ography (CT) or MRI of the brain was performed on
almost all study patients, but a small portion (n¼ 22)
of asymptomatic patients did not have a brain scan.
Most patients underwent a Doppler ultrasound
examination, and all but one had either CT- or MR-
angiography (CTA, MRA) of the carotid arteries.
Carotid endarterectomies were performed according
to the prevailing clinical standards. (More specifically,
see Supplemental file p.2).
Assessment of the origin of clinical symptoms:
plaque-derived or not
CEA patients occasionally had other potential aetiolo-
gies (e.g. atrial fibrillation or small vessel disease) for
the clinical symptom in addition to the carotid athero-
sclerosis. Two neurologists (K.N., P.I.) independently
evaluated if a patient had experienced a genuine
ischaemic cerebrovascular symptom (defined as symp-
tomatic patient), as well as whether the operated CP
had caused the thromboembolic symptoms (defined
as symptom-causing plaque). This was performed in
each case by recording all possible major and minor
aetiologies, and considering thoroughly the situation
of symptom presentation, collateral status of cerebral
circulation as well as location and extent of the puta-
tive cerebral ischemia. If the symptom was assumed
to be caused by hemodynamic mechanism rather than
thromboembolism, the symptom status was defined
as ambiguous. In case of ambiguity regarding the
symptom status of the plaque or between competing
aetiologies, a panel of stroke neurologists (P.I., K.N.,
L.S. and P.J.L.) was consulted to reach a consensus.
The diagnoses and plaque status were determined
blinded to macroscopic evaluation of plaques.
Subtypes of ischemic stroke were recorded according
to the TOAST classification [23], and the stroke risk
after TIAs was classified by the ABCD2 prognostic
score [24].
Laboratory examinations
Blood samples where taken preoperatively for clinical
purposes, as well as genotyping and biomarker assays.
See more in the Supplement pp. 2–3.
Radiology
Before recruitment, nearly all patients underwent
multi-detector CTA of the carotid arteries. If a patient
had one or several contraindications to CTA, such as
iodine allergy or severe kidney insufficiency, MRA of
the carotid arteries was performed instead. One
patient had contraindications for both CTA and MRA,
and only had a preoperative carotid artery Doppler
ultrasound. In addition, most of the patients under-
went non-enhanced brain CT before recruitment.
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HeCES 2 imaging data was analysed more extensively
than required for a standard clinico-radiological evalu-
ation (Figure 1), described in detail in the
Supplemental file p. 3. The stenosis degree (%) of
carotid arteries was calculated using the North
American Symptomatic Carotid Endarterectomy Trial
(NASCET)–criteria [25]. The stenoses were classified as
lipid-like soft, uniformly calcified (bulky calcification),
and nodular-like calcified according to the dominant
CTA plaque feature. Moreover, we recorded other
known vulnerability markers, such as ulcerations and
luminal thromboses. Over 1–2mm deep ulcerations
are visible in CTA axial images as contrast-filled
“pouches” [26].
Tissue processing and morphologic examination
Specific description and images of tissue processing,
as well as preparation for RNA, protein and lipid
analyses are provided in the Supplemental file pp. 3-6
(Supplementary Figures S1 and S2, Supplementary
Table S1). Specimens were thoroughly photographed
during tissue processing, specification is provided in
the Supplemental file p. 7 (Supplementary Figure S3).
In addition, morphologic evaluation included macro-
scopic and microscopic evaluation.
Macroscopic evaluation
Based on the experience of our expert panel we felt
that no uniform satisfactory morphological grading
method covering each of the most important plaque
characteristics exists. Therefore we developed some
new morphological grades after numerous consensus
meetings and a lead-in period (Figure 2). During tissue
processing, the carotid specimens were morphologic-
ally evaluated based on their visual and morphological
characteristics, and the macroscopic observations were
recorded in a specimen information form
(Supplementary Figure S4, Supplementary file p. 8).
The recorded parameters included six variables:
luminal thrombus, ulceration, smoothness, intraplaque
hemorrhage, atheromatous gruel, and calcification.
Both intramural and luminal calcifications were
recorded. In most instances, the luminal calcification
was different from intramural calcification, and
referred to as coral-type calcification due to a coral-
type morphologic impression. In addition, the term
“hot spot” was used for the area of the specimen
judged to be the most vulnerable and thrombogenic
area, or even considered to be the foremost likely
area having triggered the recent thromboembolic
symptom. As the name (“spot”) implicates, the “hot
spot” was often a separate (small) area differing from
the surroundings, where an ulceration or fresh throm-
bus could be seen. Details of the evaluation of the
characteristics and images of specimens representing
typical morphological features are shown in Figure 2.
Histology
Gross histological evaluation was carried out from one
representative longitudinal slice by means of two
histological stainings, Hematoxylin-Eosin (HE) and
Masson’s Trichrome (MT). Several parameters describ-
ing the general characteristics and measures of plaque
vulnerability were registered from CPs for future com-
parison with detailed immunohistochemical analysis of
the specimen, and with various patient characteristics
including biochemical, radiological and genetic infor-
mation. These parameters included: sample integrity,
correlation of histology to macroscopic findings,
Figure 1. Illustration of the used computed tomopraghy angi-
ography (CTA) classification of the internal carotid artery (ICA)
stenosis and an example of an ulcerative CP. Images A–D rep-
resent CTA axial plane source images showing the different
classifications of the ICA stenosis. Images E – H represent the
corresponding oblique sagittal maximum intensity projection
reformat images. All the images visualize a right sided ICA
stenosis. A and E¼ bulky calcification; B and F¼ soft plaque
(delineated); C and G¼ ulcerative plaque (arrow marks the
pouch of a plaque ulceration); D and H¼ calcified nodules.
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plaque surface irregularity, overall plaque stability,
intraplaque hemorrhage, fibrous cap thickness and
rupture, plaque and cap inflammation, lipid core,
thrombus, calcification, fibrous, cholesterol crystals,
cellularity, neovessels and foam cells. Comprehensive
information and details of the histological assessment
are provided in the Supplemental file pp. 9–11
(Supplementary Tables S2 and S3).
Figure 2. Morphologic characteristics and their evaluation criteria. Several characteristics were often observed in one specimen.
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HeCES-BEST
A specific substudy for consenting patients with
hemodynamically significant stenosis (high-grade,
exceeding 70% by NASCET criteria, projected n¼ 100)
was launched during HeCES 2 study for a closer look
into the effects of a potential perfusion deficit on the
eye and brain parenchyma, as well as the endothelial
function (Brain and Eye SubsTudy, HeCES-BEST). More
details of this substudy are provided in the
Supplemental file p. 12.
Follow-up
By the initiation of our study, the study patients have
also consented to the follow-up of their health and
medical data throughout the study. Information on
recurrent cerebrovascular symptoms (TIA, stroke), car-
diac events (myocardial infarctions, unstable angina,
occurrence of atrial fibrillation) and other thrombo-
embolic diseases will be retrieved from the National
Care Register for Health Care up until 10 years from
the recruitment. Deaths and the causes of death are
collected from the Finnish public authority Statistics
Finland. Study patients will be contacted no later than
10 years after their CEA, at which time they will be
interviewed. A Doppler ultrasound examination will be
performed in order to detect possible restenosis.
Clinical records on general health, vascular events,
medication and blood pressure will be revisited. Blood
samples will be obtained as well.
Findings to date
During the main recruitment period altogether 500
patients were recruited. CEA patients operated in the
Department of Vascular Surgery at the Helsinki
University Hospital (HUH) were recruited in a consecu-
tive fashion. During the recruitment period altogether
671 CEAs were performed to 631 patients, while non-
recruitment due to exclusion criteria or planned study
cessations during holidays was only 131 patients. Due
to various reasons, sporadic study patients did not
undergo CEA (n¼ 8) or the CP was lost (n¼ 7). A pro-
portion of study patients (n¼ 35) underwent CEA to
the contralateral asymptomatic side in a staged man-
ner so that the operations were carried out at intervals
of at least one month. Hence, the yield of CPs during
the period October 2012 – September 2015 was
n¼ 520 (Supplementary Figure S5, Supplemental file
p. 13). Perioperative mortality was 0.4% (2 deaths
within 1 month postoperatively) but these deaths
were unrelated to the CEA. Nine patients out of 492
suffered from major postoperative stroke (Modified
Rankin Scale 3) resulting in a complication rate of
1.8%.
Baseline characteristics and symptomatology.
Clinical characteristics at the time of CEA are pre-
sented in the Supplemental file (Supplementary Table
S4, p.14). There were more men (68%) than women
among study patients, which reflects the general gen-
der distribution of advanced carotid artery disease.
The mean age of study patients was 69.8 years, rang-
ing from 44.0 to 91.0 years.
Based on the stringent consensus diagnoses by
stroke neurologist panel, 413 (83%) of the 500 study
patients had experienced a cerebrovascular symptom,
67 (13%) were asymptomatic and 20 (4%) had an
unspecified symptom, that is, not possible to deter-
mine whether it represented a cerebrovascular or an
alternative symptomatology such as epileptic, migrain-
ous or musculoskeletal. More specific division of the
symptom status of patients and CPs is presented in
Figure 3. All strokes were classified into subtypes
according to the TOAST classification system [23]
(Supplementary Figure S6, Supplemental file p. 15).
The results of the macroscopic grading are pre-
sented in Figure 4. Typically, one plaque had several
macroscopic changes which are defined in Figure 2.
The percentages of the macroscopic characteristics
present were as follows: smoothness 62%, ulceration
61%, intraplaque hemorrhage 60%, atheromatous
gruel 59%, “hot spot” 53%, luminal coral-type calcifica-
tion 34%, abundant (44%) and moderate (39%) intra-
mural calcification, luminal thrombus of moderate size
(29%) and of abundant size (16%), and ulceration
pouch 19%.
Discussion
Currently available screening and diagnostic methods
are insufficient to identify the persons before a
thromboembolic ischaemic stroke occurs. The concept
of the vulnerable, unstable atherosclerotic plaque has
promised new avenues of opportunity in the field of
cardiovascular medicine, but the promises have yet to
realize. While the rupture-prone plaques have a predi-
lection segment in the carotid bifurcation, various
types of atherosclerotic plaques with high likelihood
of thrombotic complications and rapid progression
should be considered as vulnerable plaques [27].
Therefore, we wish to include among the vulnerable
plaques not only the unstable rupture-prone but also
the stable erosion-prone carotid plaques. Circulating
506 K. NUOTIO ET AL.
Figure 4. The proportion of macroscopic characteristics in carotid plaques. All characteristics were divided into two categories:
0¼ not present or 1¼ present, except intramural calcification and luminal thrombus, that had three different categories: 0¼ not
present, 1¼moderately present, 2¼ abundantly present.
Figure 3. HeCES2 study patients and carotid plaques – origin of symptoms. 413 (83%) of the 500 study patients had experienced
a cerebrovascular symptom, 67 (13%) were asymptomatic and 20 (4%) had an unspecified symptom, that is not possible to deter-
mine whether it represented a cerebrovascular or an alternative symptomatology such as epileptic, migrainous or musculoskeletal.
Among the 413 study patients with a cerebrovascular symptom, the operated CP was determined to be symptom-causing in 324
(79%) patients while in 35 (8%) patients it was deemed that the CP was innocent and the cerebrovascular symptom represented
another aetiology or vascular territory. In another 54 (13%) patients, coinciding competing aetiologies of cerebrovascular symp-
toms prevented to declare whether the CP was symptom-causing or not. Among the symptom-causing CPs, 161 (50%) had caused
a stroke and 163 (50%) a TIA, and further 137 (85%) of the strokes were hemispheric and 24 (15%) retinal artery occlusions,
whereas 79 (48%) of the TIAs were hemispheric and 84 (52%) were amaurosis fugax.
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blood mediators that promote thrombosis as well as
prime inflammatory vasculopathy in the distal vascular
bed also drive the progression of vulnerability to
stroke. Despite longstanding studies and large-scale
efforts, such as Athero-Express [28] and the Oxford
plaque study [29], the clinical applicability of the vul-
nerable plaque concept in carotid atherosclerosis still
remains obscure. However, due to its bilaterality, this
concept can systematically be investigated only in the
carotid artery system where strictly ipsilateral
symptom generation followed by vascular imaging
can justify symptom state-specific acquisition (i.e. CEA)
of the respective plaque specimen for detailed patho-
logical and molecular examinations. To this end, from
all 500 patients, we have described the experimental
protocol for collecting 520 CPs, from which 324 were
symptom-causing, for careful macroscopic, microscopic
and molecular investigations to follow.
Studies on the pathological substrate of coronary
artery disease have demonstrated common association
between acute myocardial infarction and rupture or
erosion of a coronary atherosclerotic plaque [30]. This
observation has led to the paradigm of a “high-risk”,
rupture-prone vulnerable plaque that could be identi-
fied and treated to prevent atherothrombotic events.
Definitive proof of the vulnerable plaque being the
very substrate of acute coronary events, remains, how-
ever, elusive because animal or human data support-
ing a cause-and-effect relationship are lacking [31,32].
Moreover, despite major advancements in imaging
technology, clinical studies have not been able to
demonstrate improved stroke risk prediction when
compared to traditional approaches of risk prediction.
In view of the existence of also clinically silent coron-
ary plaque ruptures, investigators of coronary disease
are turning from the vulnerable plaque paradigm to
alternative, multifaceted hypotheses of the natural his-
tory of atherosclerotic plaque rupture [33].
More specifically, a temporal shift from vulnerable
plaques to more stable plaques both in coronary and
carotid arteries has been recently observed [34,35].
Thus, plaques underlying thromboembolic cerebrovas-
cular event nowadays reveal more fibrous and non-
inflammatory characteristics compared with those
some ten years ago [36]. Thus, a paradigm shift from
rupture of an unstable plaque to endothelial erosion
of a stable plaque has taken place. The authors con-
sidered favourable changes in the major risk factors of
ASCVD due to life-style changes and favourable effects
of the widespread usage of statins as likely reasons for
the shift from unstable to stable plaque as a cause of
an atherothrombotic clinical event.
In addition to the accustomed methodology of
morphologic plaque analysis, such as microscopic his-
topathologic examinations, the present study introdu-
ces a more unconventional and unique ex vivo gross
morphological approach to complement the morpho-
logic characterization of a CP. By combining plaque
data from histologic examinations with macroscopic
morphology as well as radiologic information, we aim
at discovering new morphologic plaque features rela-
tive to plaque vulnerability and symptom generation.
Vice versa, new degree of knowledge might be gained
concerning the interpretation of carotid artery CTA by
corroborating the radiologic characteristics with histo-
logic and gross macroscopic findings ultimately lead-
ing to facilitated and accelerated decision making in
clinical practice.
In the previous HeCES cohort of 92 patients, we
were able to profile the gene expression pattern of
symptom-causing CP, the molecular “fingerprint” of
the culprit lesion [15]. In that early cohort, 54% of the
patients had not been receiving statins preoperatively,
and thus about half of the patients were lacking the
potential carotid plaque-stabilizing effects of this class
of drugs [37]. The present study includes a significant
number of silent plaques, enabling us to replicate
these findings and confirm the molecular “fingerprint”
of the culprit lesion in the present era of widespread
statin use.
To focus purely in carotid artery disease in trigger-
ing thromboembolic strokes, our previous HeCES
cohort excluded patients with AF and other potential
sources of cardiogenic emboli [9–11,18–20]. The pre-
sent study, however, included 86 (17%) patients with
AF. In the face of ever increasing AF epidemic, we are
planning to try our putative biomarkers and imaging
signs to extend their resolution in differentiating
symptom-causing thromboembolic carotid plaques
from silent ones even in this demanding subpopula-
tion. In keeping with the consecutive nature of enrol-
ment, this approach improves the versatility of the
eventual results in relating them to a heterogeneous,
real-life population of carotid atherosclerosis with
common co-morbidities, with a diverse panel of
antithrombotic medications and with other confound-
ing conditions.
Even with modern imaging, the neurological delin-
eation of a patient’s symptom is sometimes a chal-
lenging task. A cerebrovascular symptom is seldom
crystal-clear, not even sudden right hemiparesis, with
speech difficulty or diplopia with balance disturbance.
When symptoms present with adjunct nonspecific fea-
tures, penetrating clinical experience to accurately
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interpret patients’ symptoms is often required. At
times, the arterial anatomy and collateral pathways
evolved over time may diverge so that ischemia pre-
cipitated from carotid circulation presents as symp-
toms more typical for posterior cerebral circulation or
vice versa. The decision explained previously did not
ease our challenges as neurologists in dissecting the
individual symptom-precipitating mechanisms - large
artery thromboembolic, cardioembolic, hemodynamic
or small vessel vascular occlusions - during almost
everlasting, yet highly entertaining prerogative delib-
erations on most likely hypotheses. Infallible aetiopa-
thogenetic classification can never be achieved, and
for this reason, we arrived at classifying 54 (11%)
patients to a group in which it could not be deter-
mined whether the plaque or a competing aetiology
had precipitated the clinical symptom. Furthermore,
we included 20 (4%) patients to a group with an
ambiguous symptom, meaning that eventually it was
not possible to determine whether the symptom was
of cerebrovascular nature or due to some other neuro-
logical disturbance occurring ipsilaterally to the oper-
ated carotid artery.
For scientific purposes, the present study pays par-
ticular attention to the accuracy of the evaluation of
the neurological symptoms of the patients, and, more-
over, to the detailed macroscopic, microscopic, and
molecular architecture of the endarterectomized CPs.
In this study, it took two to four stroke neurologists to
evaluate the symptom status with the aid of radiologic
data as well as available medical records, while in daily
clinical practice often hefty therapy decisions must be
made with a smaller manpower. Erroneous initial inter-
pretation of the symptom status waters down all
otherwise sophisticated results and eloquent projec-
tions of individual disease course, and even endangers
patients to flawed therapeutic regimens. It is for this
purpose that the study aims to find novel biomarkers
and imaging hallmarks, and thereby to provide clini-
cians some trustworthy tools to judge whether a given
plaque is likely going to destroy the few remaining
years of an elderly patient, or is prone to stay inno-
cent through the projected remaining ‘good years’.
Furthermore, benefit can be expected through identifi-
cation of novel molecular targets for drug
development.
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